AI Article Synopsis
- - The study reviewed patch test results of patients taking the immunosuppressant methotrexate (MTX) at the University of North Carolina Dermatology from 2010 to 2019, aiming to determine its effect on testing outcomes.
- - Among 674 patients, those on MTX had a positivity rate of 46.8%, compared to 53.4% for the control group, with no significant differences in reactions between the two groups.
- - The findings suggest that methotrexate does not adversely affect patch test results, indicating it can be used safely in patients undergoing patch testing.
Article Abstract
Background: Patch testing while taking systemic immunosuppressants is sometimes unavoidable. Methotrexate (MTX) is the immunosuppressant currently considered least likely to negatively impact patch testing.
Objective: The aim of the study was to characterize a cohort of patients patch tested while taking MTX.
Methods: This is a retrospective review of patients patch tested at the University of North Carolina Dermatology in Chapel Hill, North Carolina, from 2010 to 2019, comparing patch test results of patients taking MTX with those of a control group.
Results: An overall 52.8% positivity rate (356/674) was observed. Sixty two of 674 patients were patch tested while taking MTX, with a 46.8% positivity rate (29/62) compared with 53.4% (327/612) in the control group. The control group experienced 975 reactions, including 637 1+ reactions, 291 2+ reactions, and 47 3+ reactions. The MTX group experienced 50 reactions, including thirty-two 1+ reactions, fourteen 2+ reactions, and four 3+ reactions. The difference between the distributions was not statistically significant. Mean weekly MTX dose was 15.6 mg, whereas mean total accumulated dose was 251.6 mg. There was no statistically significant difference between weekly dose and total accumulated dose in patients with positive or negative results.
Conclusions: In our cohort, MTX had no discernible effect on patch test results, supporting use during patch testing with minimal false-negative risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DER.0000000000000852 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genotype-function-phenotype correlations for SCN1A variants identified by clinical genetic testing.
Ann Clin Transl Neurol
January 2025
Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Objective: Interpretation of clinical genetic testing, which identifies a potential genetic etiology in 25% of children with epilepsy, is limited by variants of uncertain significance. Understanding functional consequences of variants can help distinguish pathogenic from benign alleles. We combined automated patch clamp recording with neurophysiological simulations to discern genotype-function-phenotype correlations in a real-world cohort of children with SCN1A-associated epilepsy.
View Article and Find Full Text PDFCalretinin-expressing neurons in the basal forebrain specifically contact granule cells in the olfactory bulb and modulate odor learning.
J Neurosci
January 2025
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada, K1N 6N5
GABAergic neurons in basal forebrain (BF) nuclei project densely to all layers of the mouse main olfactory bulb (OB), the first relay in odor information processing. However, BF projection neurons are diverse and the contribution of each subtype to odor information processing is not known. In the present study, we used retrograde and anterograde tracing methods together with whole-brain light-sheet analyses, patch-clamp recordings coupled with optogenetic and chemogenetic approaches during spontaneous odor discrimination, and go/no-go odor discrimination/learning tests to characterize the synaptic targets in the OB of BF calretinin-expressing (CR+) GABAergic cells and to reveal their functional implications.
View Article and Find Full Text PDFAllergens Responsible for Contact Allergy in Children From 2010 to 2024: A Systematic Review and Meta-Analysis.
Contact Dermatitis
January 2025
Department of Dermatology and Allergy, Herlev and Gentofte-Copenhagen University Hospital, Copenhagen, Denmark.
Contact allergy (CA) is a frequent condition in children; however, newer estimates of the prevalence of CA in children are lacking. Herein, we aim to provide an estimate of the prevalence of CA in children from 2010 to 2024. Two authors independently searched PubMed, Embase and Web of Science for studies reporting the prevalence of positive patch tests (PPTs) to allergens in populations including ≥ 100 children (< 18 years).
View Article and Find Full Text PDFUse of Glad Press and Seal for Improved Patient Experience During Patch Testing.
Dermatitis
January 2025
Department of Dermatology, University of Utah, Salt Lake City, Utah, USA.
High degree of variability and lack of transparency among private insurers for coverage of comprehensive patch testing.
J Am Acad Dermatol
January 2025
Ronald L. Pearlman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!